No Cover Image

Journal article 197 views 35 downloads

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

Steve Bain Orcid Logo, Bendix Carstensen, Liselotte Hyveled, Stephanie Seremetis, Frederik Flindt Kreiner Orcid Logo, Hanan Amadid, Alice Clark

BMJ Open Diabetes Research & Care, Volume: 11, Issue: 3, Start page: e003300

Swansea University Author: Steve Bain Orcid Logo

  • 63949.VOR.pdf

    PDF | Version of Record

    © Author(s), 2023. Re-use permitted under CC BY-NC. No commercial re-use.

    Download (1.1MB)

Check full text

DOI (Published version): 10.1136/bmjdrc-2022-003300

Published in: BMJ Open Diabetes Research & Care
ISSN: 2052-4897
Published: BMJ 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63949
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-07-26T08:31:11Z
last_indexed 2023-07-26T08:31:11Z
id cronfa63949
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>63949</id><entry>2023-07-26</entry><title>Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-07-26</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>BMJ Open Diabetes Research &amp; Care</journal><volume>11</volume><journalNumber>3</journalNumber><paginationStart>e003300</paginationStart><paginationEnd/><publisher>BMJ</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2052-4897</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>6</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-06-01</publishedDate><doi>10.1136/bmjdrc-2022-003300</doi><url>http://dx.doi.org/10.1136/bmjdrc-2022-003300</url><notes>Letter</notes><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>Novo Nordisk A/S.</funders><projectreference/><lastEdited>2023-11-14T16:56:31.7596569</lastEdited><Created>2023-07-26T09:30:04.0371128</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>1</order></author><author><firstname>Bendix</firstname><surname>Carstensen</surname><order>2</order></author><author><firstname>Liselotte</firstname><surname>Hyveled</surname><order>3</order></author><author><firstname>Stephanie</firstname><surname>Seremetis</surname><order>4</order></author><author><firstname>Frederik Flindt</firstname><surname>Kreiner</surname><orcid>0000-0001-8296-453x</orcid><order>5</order></author><author><firstname>Hanan</firstname><surname>Amadid</surname><order>6</order></author><author><firstname>Alice</firstname><surname>Clark</surname><order>7</order></author></authors><documents><document><filename>63949__28327__e0e2ecd80f2340cfb887fbd806eb3d4a.pdf</filename><originalFilename>63949.VOR.pdf</originalFilename><uploaded>2023-08-18T16:16:45.2619701</uploaded><type>Output</type><contentLength>1157443</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© Author(s), 2023. Re-use permitted under CC BY-NC. No commercial re-use.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 63949 2023-07-26 Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2023-07-26 BMS Journal Article BMJ Open Diabetes Research & Care 11 3 e003300 BMJ 2052-4897 1 6 2023 2023-06-01 10.1136/bmjdrc-2022-003300 http://dx.doi.org/10.1136/bmjdrc-2022-003300 Letter COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University Another institution paid the OA fee Novo Nordisk A/S. 2023-11-14T16:56:31.7596569 2023-07-26T09:30:04.0371128 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Steve Bain 0000-0001-8519-4964 1 Bendix Carstensen 2 Liselotte Hyveled 3 Stephanie Seremetis 4 Frederik Flindt Kreiner 0000-0001-8296-453x 5 Hanan Amadid 6 Alice Clark 7 63949__28327__e0e2ecd80f2340cfb887fbd806eb3d4a.pdf 63949.VOR.pdf 2023-08-18T16:16:45.2619701 Output 1157443 application/pdf Version of Record true © Author(s), 2023. Re-use permitted under CC BY-NC. No commercial re-use. true eng http://creativecommons.org/licenses/by-nc/4.0/
title Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
spellingShingle Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
Steve Bain
title_short Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
title_full Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
title_fullStr Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
title_full_unstemmed Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
title_sort Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Steve Bain
Bendix Carstensen
Liselotte Hyveled
Stephanie Seremetis
Frederik Flindt Kreiner
Hanan Amadid
Alice Clark
format Journal article
container_title BMJ Open Diabetes Research & Care
container_volume 11
container_issue 3
container_start_page e003300
publishDate 2023
institution Swansea University
issn 2052-4897
doi_str_mv 10.1136/bmjdrc-2022-003300
publisher BMJ
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
url http://dx.doi.org/10.1136/bmjdrc-2022-003300
document_store_str 1
active_str 0
published_date 2023-06-01T16:56:35Z
_version_ 1782559272368865280
score 11.012678

Similar Items